Table 3:

Summary of primary therapy studies at the European Society for Medical Oncology 2019 Meeting

Study	Patient Population	Treatment arms			Primary Outcome	Primary Results	Ref
PRIMA (PRIMA/ ENGO - OV26/ GOG-3012)	Stage III/IV; high grade serous or endometrioid; CR or PR after 6–9 cycles of chemotherapy; must have had residual disease or were inoperable	Niraparib maintenance	Placebo		Progression-free survival in patients with HRD tumors	HRD positive: 21.9 vs 10.4 months (HR 0.43, 95% CI 0.31–0.59, p < 0.001) favoring niraparib maintenance; Entire cohort: 13.8 vs 8.2 months (HR 0.62, 95% CI 0.50–0.76, p < 0.001) favoring niraparib maintenance	[1]
PAOLA-1 (PAOLA-1/ ENGOT-ov25)	Stage III/IV high grade serous or endometrioid; must have undergone tumor debulking (primary or interval), allowed complete resection; must have received at least 3 cycles of bevacizumab as part of treatment; must have had CR or PR to chemotherapy	Olaparib + bevaciz umab mainte nance	Placebo + bevaciz umab mainte nance		Progression-free survival	22.1 vs 16.6 months (HR 0.59, 95% CI 0.49–0.72, p < 0.001) favoring olaparib maintenance	[2]
VELIA (VELIA / GOG-3005)	Stage III/IV high grade serous; primary or interval tumor debulking with either complete resection or residual disease present; did not need to have a response to chemotherapy	Carboplatin, paclitaxel, veliparib + veliparib maintenance	Carboplatin, paclitaxel, veliparib + placebo maintenance	Carboplatin, paclita xel, placebo + placebo maintenance	Progression-free survival for patients who received veliparib (treatment and maintenanc e) vs. those that received placebo (treatment and maintenance)	Women with BRCA mutation: 34.7 vs. 22.0 months (HR 0.44, 95% CI 0.28–0.68, p < 0.001); Women with HRD tumors: 31.9 vs 20.5 months (HR 0.57, 95% CI 0.43–0.76, p < 0.001); intention to treat group: 23.5 vs 17.3 months (HR 0.68, 95% CI 0.56–0.83, p < 0.001) favoring the veliparib arm	[3]